Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.
Identifieur interne : 001142 ( Main/Exploration ); précédent : 001141; suivant : 001143Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.
Auteurs : E. Tuaillon [France] ; K. Bolloré [France] ; A. Pisoni [France] ; S. Debiesse [France] ; C. Renault [France] ; S. Marie [France] ; S. Groc [France] ; C. Niels [France] ; N. Pansu [France] ; A M Dupuy [France] ; D. Morquin [France] ; V. Foulongne [France] ; A. Bourdin [France] ; V. Le Moing [France] ; P. Van De Perre [France]Source :
- The Journal of infection [ 1532-2742 ] ; 2020.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Anticorps antiviraux (sang), Betacoronavirus (immunologie), Femelle (MeSH), Hospitalisation (statistiques et données numériques), Humains (MeSH), Infections à coronavirus (diagnostic), Infections à coronavirus (immunologie), Jeune adulte (MeSH), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (immunologie), Sensibilité et spécificité (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Systèmes automatisés lit malade (MeSH), Séroconversion (MeSH), Techniques de laboratoire clinique (MeSH), Test ELISA (MeSH), Tests sérologiques (MeSH), Trousses de réactifs pour diagnostic (MeSH).
- MESH :
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- immunologie : Betacoronavirus, Infections à coronavirus, Pneumopathie virale.
- sang : Anticorps antiviraux.
- statistiques et données numériques : Hospitalisation.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Pandémies, Sensibilité et spécificité, Sujet âgé, Sujet âgé de 80 ans ou plus, Systèmes automatisés lit malade, Séroconversion, Techniques de laboratoire clinique, Test ELISA, Tests sérologiques, Trousses de réactifs pour diagnostic.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Viral (blood), Betacoronavirus (immunology), Clinical Laboratory Techniques (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (immunology), Enzyme-Linked Immunosorbent Assay (MeSH), Female (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (immunology), Point-of-Care Systems (MeSH), Reagent Kits, Diagnostic (MeSH), Sensitivity and Specificity (MeSH), Seroconversion (MeSH), Serologic Tests (MeSH), Young Adult (MeSH).
- MESH :
- chemical , blood : Antibodies, Viral.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- immunology : Betacoronavirus, Coronavirus Infections, Pneumonia, Viral.
- statistics & numerical data : Hospitalization.
- Adolescent, Adult, Aged, Aged, 80 and over, Clinical Laboratory Techniques, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Pandemics, Point-of-Care Systems, Reagent Kits, Diagnostic, Sensitivity and Specificity, Seroconversion, Serologic Tests, Young Adult.
Abstract
OBJECTIVES
SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests.
METHODS
In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA.
RESULTS
Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell® POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon).
CONCLUSIONS
The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.
DOI: 10.1016/j.jinf.2020.05.077
PubMed: 32504735
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.</title><author><name sortKey="Tuaillon, E" sort="Tuaillon, E" uniqKey="Tuaillon E" first="E" last="Tuaillon">E. Tuaillon</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France. Electronic address: e-tuaillon@chu-montpellier.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Bollore, K" sort="Bollore, K" uniqKey="Bollore K" first="K" last="Bolloré">K. Bolloré</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Pisoni, A" sort="Pisoni, A" uniqKey="Pisoni A" first="A" last="Pisoni">A. Pisoni</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Debiesse, S" sort="Debiesse, S" uniqKey="Debiesse S" first="S" last="Debiesse">S. Debiesse</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Renault, C" sort="Renault, C" uniqKey="Renault C" first="C" last="Renault">C. Renault</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Marie, S" sort="Marie, S" uniqKey="Marie S" first="S" last="Marie">S. Marie</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Groc, S" sort="Groc, S" uniqKey="Groc S" first="S" last="Groc">S. Groc</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Niels, C" sort="Niels, C" uniqKey="Niels C" first="C" last="Niels">C. Niels</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Pansu, N" sort="Pansu, N" uniqKey="Pansu N" first="N" last="Pansu">N. Pansu</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Dupuy, A M" sort="Dupuy, A M" uniqKey="Dupuy A" first="A M" last="Dupuy">A M Dupuy</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Morquin, D" sort="Morquin, D" uniqKey="Morquin D" first="D" last="Morquin">D. Morquin</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Foulongne, V" sort="Foulongne, V" uniqKey="Foulongne V" first="V" last="Foulongne">V. Foulongne</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Bourdin, A" sort="Bourdin, A" uniqKey="Bourdin A" first="A" last="Bourdin">A. Bourdin</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Le Moing, V" sort="Le Moing, V" uniqKey="Le Moing V" first="V" last="Le Moing">V. Le Moing</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Van De Perre, P" sort="Van De Perre, P" uniqKey="Van De Perre P" first="P" last="Van De Perre">P. Van De Perre</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32504735</idno><idno type="pmid">32504735</idno><idno type="doi">10.1016/j.jinf.2020.05.077</idno><idno type="wicri:Area/Main/Corpus">000F34</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F34</idno><idno type="wicri:Area/Main/Curation">000F34</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F34</idno><idno type="wicri:Area/Main/Exploration">000F34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.</title><author><name sortKey="Tuaillon, E" sort="Tuaillon, E" uniqKey="Tuaillon E" first="E" last="Tuaillon">E. Tuaillon</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France. Electronic address: e-tuaillon@chu-montpellier.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Bollore, K" sort="Bollore, K" uniqKey="Bollore K" first="K" last="Bolloré">K. Bolloré</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Pisoni, A" sort="Pisoni, A" uniqKey="Pisoni A" first="A" last="Pisoni">A. Pisoni</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Debiesse, S" sort="Debiesse, S" uniqKey="Debiesse S" first="S" last="Debiesse">S. Debiesse</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Renault, C" sort="Renault, C" uniqKey="Renault C" first="C" last="Renault">C. Renault</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Marie, S" sort="Marie, S" uniqKey="Marie S" first="S" last="Marie">S. Marie</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Groc, S" sort="Groc, S" uniqKey="Groc S" first="S" last="Groc">S. Groc</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Niels, C" sort="Niels, C" uniqKey="Niels C" first="C" last="Niels">C. Niels</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Pansu, N" sort="Pansu, N" uniqKey="Pansu N" first="N" last="Pansu">N. Pansu</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Dupuy, A M" sort="Dupuy, A M" uniqKey="Dupuy A" first="A M" last="Dupuy">A M Dupuy</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Morquin, D" sort="Morquin, D" uniqKey="Morquin D" first="D" last="Morquin">D. Morquin</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Foulongne, V" sort="Foulongne, V" uniqKey="Foulongne V" first="V" last="Foulongne">V. Foulongne</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Bourdin, A" sort="Bourdin, A" uniqKey="Bourdin A" first="A" last="Bourdin">A. Bourdin</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Le Moing, V" sort="Le Moing, V" uniqKey="Le Moing V" first="V" last="Le Moing">V. Le Moing</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Van De Perre, P" sort="Van De Perre, P" uniqKey="Van De Perre P" first="P" last="Van De Perre">P. Van De Perre</name><affiliation wicri:level="3"><nlm:affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author></analytic><series><title level="j">The Journal of infection</title><idno type="eISSN">1532-2742</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antibodies, Viral (blood)</term><term>Betacoronavirus (immunology)</term><term>Clinical Laboratory Techniques (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (immunology)</term><term>Enzyme-Linked Immunosorbent Assay (MeSH)</term><term>Female (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (immunology)</term><term>Point-of-Care Systems (MeSH)</term><term>Reagent Kits, Diagnostic (MeSH)</term><term>Sensitivity and Specificity (MeSH)</term><term>Seroconversion (MeSH)</term><term>Serologic Tests (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps antiviraux (sang)</term><term>Betacoronavirus (immunologie)</term><term>Femelle (MeSH)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (immunologie)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (immunologie)</term><term>Sensibilité et spécificité (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Systèmes automatisés lit malade (MeSH)</term><term>Séroconversion (MeSH)</term><term>Techniques de laboratoire clinique (MeSH)</term><term>Test ELISA (MeSH)</term><term>Tests sérologiques (MeSH)</term><term>Trousses de réactifs pour diagnostic (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Clinical Laboratory Techniques</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Point-of-Care Systems</term><term>Reagent Kits, Diagnostic</term><term>Sensitivity and Specificity</term><term>Seroconversion</term><term>Serologic Tests</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Sensibilité et spécificité</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Systèmes automatisés lit malade</term><term>Séroconversion</term><term>Techniques de laboratoire clinique</term><term>Test ELISA</term><term>Tests sérologiques</term><term>Trousses de réactifs pour diagnostic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell® POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32504735</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J. Infect.</ISOAbbreviation></Journal><ArticleTitle>Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.</ArticleTitle><Pagination><MedlinePgn>e39-e45</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(20)30376-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2020.05.077</ELocationID><Abstract><AbstractText Label="OBJECTIVES">SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests.</AbstractText><AbstractText Label="METHODS">In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA.</AbstractText><AbstractText Label="RESULTS">Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell® POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon).</AbstractText><AbstractText Label="CONCLUSIONS">The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tuaillon</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France. Electronic address: e-tuaillon@chu-montpellier.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolloré</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisoni</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debiesse</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renault</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marie</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groc</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niels</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pansu</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuy</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morquin</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foulongne</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourdin</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Moing</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van de Perre</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS; CHU Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011933">Reagent Kits, Diagnostic</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000657964">COVID-19 diagnostic testing</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019411" MajorTopicYN="Y">Clinical Laboratory Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="Y">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011933" MajorTopicYN="N">Reagent Kits, Diagnostic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="Y">Seroconversion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012698" MajorTopicYN="N">Serologic Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">ELISA</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2 antibodies</Keyword><Keyword MajorTopicYN="Y">point of care tests</Keyword></KeywordList><CoiStatement>Conflict of Interest The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32504735</ArticleId><ArticleId IdType="pii">S0163-4453(20)30376-5</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2020.05.077</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li></region><settlement><li>Montpellier</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Tuaillon, E" sort="Tuaillon, E" uniqKey="Tuaillon E" first="E" last="Tuaillon">E. Tuaillon</name></region><name sortKey="Bollore, K" sort="Bollore, K" uniqKey="Bollore K" first="K" last="Bolloré">K. Bolloré</name><name sortKey="Bourdin, A" sort="Bourdin, A" uniqKey="Bourdin A" first="A" last="Bourdin">A. Bourdin</name><name sortKey="Debiesse, S" sort="Debiesse, S" uniqKey="Debiesse S" first="S" last="Debiesse">S. Debiesse</name><name sortKey="Dupuy, A M" sort="Dupuy, A M" uniqKey="Dupuy A" first="A M" last="Dupuy">A M Dupuy</name><name sortKey="Foulongne, V" sort="Foulongne, V" uniqKey="Foulongne V" first="V" last="Foulongne">V. Foulongne</name><name sortKey="Groc, S" sort="Groc, S" uniqKey="Groc S" first="S" last="Groc">S. Groc</name><name sortKey="Le Moing, V" sort="Le Moing, V" uniqKey="Le Moing V" first="V" last="Le Moing">V. Le Moing</name><name sortKey="Marie, S" sort="Marie, S" uniqKey="Marie S" first="S" last="Marie">S. Marie</name><name sortKey="Morquin, D" sort="Morquin, D" uniqKey="Morquin D" first="D" last="Morquin">D. Morquin</name><name sortKey="Niels, C" sort="Niels, C" uniqKey="Niels C" first="C" last="Niels">C. Niels</name><name sortKey="Pansu, N" sort="Pansu, N" uniqKey="Pansu N" first="N" last="Pansu">N. Pansu</name><name sortKey="Pisoni, A" sort="Pisoni, A" uniqKey="Pisoni A" first="A" last="Pisoni">A. Pisoni</name><name sortKey="Renault, C" sort="Renault, C" uniqKey="Renault C" first="C" last="Renault">C. Renault</name><name sortKey="Van De Perre, P" sort="Van De Perre, P" uniqKey="Van De Perre P" first="P" last="Van De Perre">P. Van De Perre</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001142 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001142 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32504735
|texte= Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32504735" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |